Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease.
Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease.
复制标题
DOI：
10.1002/mds.28641
复制
发表时间：
2021-08
期刊：
影响因子：
--
通讯作者：
Simuni T
中科院分区：
文献类型：
--
作者：
Marras C;Mills KA;Eberly S;Oakes D;Chou KL;Halverson M;Parashos SA;Tarolli CG;Lai JS;Nowinsky CJ;Suchowersky O;Farbman ES;Shulman LM;Simuni T
神经疾病患者的生活质量（neuroqol）是一个公开的与健康相关的生活质量测量系统。评价神经生活质量信息库作为帕金森病临床试验结果测量指标的效用。多中心临床试验队列中神经-生活质量对变化的反应性及结构效度分析。在超过3年的310名参与者中，8个neuroqol域中有5个的变化是显著的（p<0.05），但非常温和。认知和行动领域的效应量最大（0.35-0.39）。在左旋多巴开始治疗的一年中，对下肢功能-活动能力的影响最大，为- 0.19。对于类似设计的临床试验，证明恶化减少50%所需的估计样本量为每组420至1000多名参与者。作为早期帕金森氏病的结果衡量标准，将需要更灵敏的工具。
The Quality of Life in Neurological Disorders (Neuro-QoL) is a publicly available health-related quality of life measurement system. To evaluate utility of Neuro-QoL item banks as outcome measures for clinical trials in Parkinson’s disease. An analysis of Neuro-QoL responsiveness to change and construct validity in a multicenter clinical trial cohort. Among 310 participants over 3 years, changes in five of eight Neuro-QoL domains were significant (p<0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35–0.39). The largest effect size for change over the year in which levodopa was initiated was −0.19 for lower extremity function - mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to over 1000 participants per group. To serve as an outcome measure in early Parkinson’s disease more sensitive tools will be required.